Anemia in Heart Failure: Still Relevant?

JACC: Heart Failure

Volumn 6, Issue 3, 2018, Pages 201-208

  Grote Beverborg, Niels ^a   van Veldhuisen, Dirk J ^a   van der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

anemia; erythropoiesis stimulating agents; heart failure; iron

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRIC CARBOXYMALTOSE; HEMOGLOBIN; HEPCIDIN; IRON; IRON POLYSACCHARIDE; IRON SACCHARATE; LEXAPTEPID PEGOL; LY 2787106; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; SPIEGELMER; UNCLASSIFIED DRUG; FERRITIN;

ANEMIA; CARCINOGENESIS; DRUG TARGETING; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; BLOOD TRANSFUSION; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL ILLUSTRATION; MEDICAL RESEARCH; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA; BIOMEDICAL RESEARCH; BLOOD TRANSFUSION; FERRITINS; HEART FAILURE; HEMATINICS; HEPCIDINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MEDICAL ILLUSTRATION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85033394211     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.08.023     Document Type: Review

References (49)

1. van Veldhuisen, D.J., Anker, S.D., Ponikowski, P., Macdougall, I.C., Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8 (2011), 485–493.
2. Adlbrecht, C., Kommata, S., Hülsmann, M., et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 29 (2008), 2343–2350.
3. Grote Beverborg, N., Verweij, N., Klip, I.T., et al. Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates. PLoS One, 10, 2015, e0125215.
4. Groenveld, H.F., Januzzi, J.L., Damman, K., et al. Anemia and mortality in heart failure patients. a systematic review and meta-analysis. J Am Coll Cardiol 52 (2008), 818–827.
5. Tang, W.H., Tong, W., Jain, A., Francis, G.S., Harris, C.M., Young, J.B., Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol 51 (2008), 569–576.
6. Waldum, B., Westheim, A.S., Sandvik, L., et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol 59 (2012), 371–378.
7. Klip, I.T., Comin-Colet, J., Voors, A.A., et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165 (2013), 575–582.e3.
8. Okonko, D.O., Mandal, A.K., Missouris, C.G., Poole-Wilson, P.A., Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58 (2011), 1241–1251.
9. Nanas, J.N., Matsouka, C., Karageorgopoulos, D., et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48 (2006), 2485–2489.
10. van der Meer, P., Lok, D.J., Januzzi, J.L., et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 29 (2008), 1510–1515.
11. Westenbrink, B.D., Visser, F.W., Voors, A.A., et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 28 (2007), 166–171.
12. Westenbrink, B.D., Voors, A.A., De Boer, R.A., et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 12 (2010), 676–684.
13. van der Meer, P., Voors, A.A., Lipsic, E., Smilde, T.D.J., van Gilst, W.H., van Veldhuisen, D.J., Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44 (2004), 63–67.
14. Grote Beverborg, N., van der Wal, H.H., Klip, I.T., et al. High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. Eur J Heart Fail 18 (2016), 814–821.
15. van der Meer, P., Lipsic, E., Westenbrink, B.D., et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112 (2005), 1743–1747.
16. Ishani, A., Weinhandl, E., Zhao, Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45 (2005), 391–399.
17. Komajda, M., Anker, S.D., Charlesworth, A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27 (2006), 1440–1446.
18. Weiskopf, R.B., Viele, M.K., Feiner, J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 279 (1998), 217–221.
19. Ebner, N., Jankowska, E.A., Ponikowski, P., et al. The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure. Int J Cardiol 205 (2016), 6–12.
20. Klip, I.T., Jankowska, E.A., Enjuanes, C., et al. The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur J Heart Fail 16 (2014), 655–662.
21. Garty, M., Cohen, E., Zuchenko, A., et al. Blood transfusion for acute decompensated heart failure—friend or foe?. Am Heart J 158 (2009), 653–658.
22. Kao, D.P., Kreso, E., Fonarow, G.C., Krantz, M.J., Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000-2006). Am J Cardiol 107 (2011), 69–73.
23. Qaseem, A., Humphrey, L.L., Fitterman, N., Starkey, M., Shekelle, P., Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 159 (2013), 770–779.
24. Swedberg, K., Young, J.B., Anand, I.S., et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368 (2013), 1210–1219.
25. Bello, N.A., Lewis, E.F., Desai, A.S., et al. Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. Eur J Heart Fail 17 (2015), 1201–1207.
26. Bennett, C.L., Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA, 299, 2008, 914.
27. Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006), 2085–2098.
28. Kleijn, L., Belonje, A.M., Voors, A.A., et al. Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart 98 (2012), 1237–1241.
29. Borovka, M., Teruya, S., Alvarez, J., Helmke, S., Maurer, M.S., Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the Heart Failure With Preserved Ejection Fraction (HFPEF) anemia trial. J Card Fail 19 (2013), 685–691.
30. van Veldhuisen, D.J., Pfeffer, M.A., van der Meer, P., Olson, K., Solomon, S.D., Abstract 1293: hyporesponsiveness to darbepoetin alfa in patients with heart failure and anemia in the RED-HF study: clinical and prognostic associations. Eur J Heart Fail, 17, 2015, 269.
31. Lewis, G.D., Semigran, M.J., Givertz, M.M., et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail, 9, 2016, e000345.
32. Toblli, J.E., Lombraña, A., Duarte, P., Di Gennaro, F., Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007), 1657–1665.
33. Okonko, D.O., Grzeslo, A., Witkowski, T., et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51 (2008), 103–112.
34. Anker, S.D., Comin Colet, J., Filippatos, G., et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.
35. Ponikowski, P., Van Veldhuisen, D.J., Comin-Colet, J., et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36 (2015), 657–668.
36. van Veldhuisen, D.J., Ponikowski, P., van der Meer, P., et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136 (2017), 1374–1383.
37. Grote Beverborg, N., van der Meer, P., Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients. (abstr) Eur J Heart Fail 19 (2017), 20–21.
38. Anker, S.D., Kirwan, B.A., van Veldhuisen, D.J., et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 20 (2018), 125–133.
39. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37 (2016), 2129–2200.
40. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
41. Vadhan-Raj, S., Abonour, R., Goldman, J.W., et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol, 10, 2017, 73.
42. van Eijk, L.T., John, A.S., Schwoebel, F., et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124 (2014), 2643–2646.
43. Ruckle, J., Jacobs, M., Kramer, W., et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24 (2009), 744–752.
44. Havill, J., Kopyt, N., Coyne, D., Weiswasser, M., Smith, W., Sotatercept improves anemia, vascular calcification, and bone loss in patients with end-stage kidney disease on hemodialysis. (Abstr. TH-PO038) J Am Soc Nephrol 26 (2015), 310A–311A.
45. Paulson, R.F., Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med 20 (2014), 334–335.
46. Iancu-Rubin, C., Mosoyan, G., Wang, J., Kraus, T., Sung, V., Hoffman, R., Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol 41 (2013), 155–166.e17.
47. Semenza, G.L., Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8 (1998), 588–594.
48. Bonomini, M., Del Vecchio, L., Sirolli, V., Locatelli, F., New treatment approaches for the anemia of CKD. Am J Kidney Dis 67 (2016), 133–142.
49. Chen, N., Qian, J., Chen, J., et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 32 (2017), 1373–1386.